⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1879074 | 1.00 | — | — | |
| SCHEMBL152150 | 1.00 | — | — | |
| SCHEMBL9203898 | 1.00 | — | — | |
| SCHEMBL2724423 | 1.00 | — | — | |
| SCHEMBL532330 | 1.00 | — | — | |
| SCHEMBL152149 | 1.00 | — | — | |
| SCHEMBL1870963 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL1922314 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL3442349 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL15568382 | 0.97 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12466815-B2 | Carboxamide compounds and uses thereof | INCYTE CORPORATION (US) | 2025-11-11 | — | — | US | disclosed |
| US-20240150326-A1 | CARBOXAMIDE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2024-05-09 | — | — | US | disclosed |
| CN-117486885-A | Use of pyrazolopyrimidines | 中国科学院上海药物研究所 | 2024-02-02 | — | — | CN | disclosed |
| US-20230265090-A1 | QUINAZOLINE COMPOUND | MEDSHINE DISCOVERY INC. (CN) | 2023-08-24 | — | — | US | disclosed |
| US-20230265090-A1 | QUINAZOLINE COMPOUND | MEDSHINE DISCOVERY INC. (CN) | 2023-08-24 | — | — | US | disclosed |
| EP-4186903-A1 | QUINAZOLINE COMPOUND | Medshine Discovery Inc. (CN) | 2023-05-31 | — | — | EP | disclosed |
| WO-2023051628-A1 | SOS1 INHIBITORS HAVING PYRIDO SIX-MEMBERED RING STRUCTURE | 上海海和药物研究开发股份有限公司 | 2023-04-06 | — | — | WO | disclosed |
| EP-3774843-B1 | DIPEPTIDE PIPERIDINE DERIVATIVES | MOLECURE SA (PL) | 2022-05-25 | — | — | EP | disclosed |
| EP-3755703-B1 | N-(PHENYL)-2-(PHENYL)PYRIMIDINE-4-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS HPK1 INHIBITORS FOR TREATING CANCER | INCYTE CORP (US) | 2022-05-04 | — | — | EP | disclosed |
| EP-3774843-A1 | DIPEPTIDE PIPERIDINE DERIVATIVES | Oncoarendi Therapeutics SA (PL) | 2021-02-17 | — | — | EP | disclosed |
| EP-1643998-B1 | DUAL NK1/NK3 ANTAGONISTS FOR TREATING SCHIZOPHRENIA | HOFFMANN LA ROCHE (CH) | 2007-08-29 | — | — | EP | disclosed |
| EP-1643998-B1 | DUAL NK1/NK3 ANTAGONISTS FOR TREATING SCHIZOPHRENIA | HOFFMANN LA ROCHE (CH) | 2007-08-29 | — | — | EP | disclosed |
| US-20070161620-A1 | ISOQUINOLINE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI PHARMA CORPORATION (JP) | 2007-07-12 | — | — | US | disclosed |
| US-7220759-B2 | Isoquinoline compound and pharmaceutical use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2007-05-22 | — | — | US | disclosed |
| EP-1643998-A1 | DUAL NK1/NK3 ANTAGONISTS FOR TREATING SCHIZOPHRENIA | F. HOFFMANN-LA ROCHE AG (CH) | 2006-04-12 | — | — | EP | disclosed |
| US-20050090533-A1 | Dual NK1/NK3 receptor antagonists | F. HOFMANN-LA ROCHE AG (CH) | 2005-04-28 | — | — | US | disclosed |
| WO-2005002577-A1 | DUAL NK1/NK3 ANTAGONISTS FOR TREATING SCHIZOPHRENIA | F. HOFFMANN-LA ROCHE AG (CH) | 2005-01-13 | — | — | WO | disclosed |
| US-20040248931-A1 | Isoquinoline compound and pharmaceutical use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2004-12-09 | — | — | US | disclosed |
| US-6573377-B1 | Antitumor agent capable of showing its efficacy even against 5- FU drug resistant tumors | DAIICHI PHARMACEUTICALS CO., LTD. (JP) | 2003-06-03 | — | — | US | disclosed |
| EP-1103551-A1 | PYRAZOLE DERIVATIVES AND SALTS THEREOF | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2001-05-30 | — | — | EP | disclosed |